PolyPeptide Group AG

BATS-CHIXE:PPGNZ Stock Report

Market Cap: CHF 921.9m

PolyPeptide Group Valuation

Is PPGNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PPGNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PPGNZ (CHF27.35) is trading above our estimate of fair value (CHF21.99)

Significantly Below Fair Value: PPGNZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PPGNZ?

Key metric: As PPGNZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PPGNZ. This is calculated by dividing PPGNZ's market cap by their current revenue.
What is PPGNZ's PS Ratio?
PS Ratio3.1x
Sales€323.58m
Market Cap€990.01m

Price to Sales Ratio vs Peers

How does PPGNZ's PS Ratio compare to its peers?

The above table shows the PS ratio for PPGNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.5x
ONT Oxford Nanopore Technologies
7.3x22.6%UK£1.2b
ERGO Ergomed
4.6x8.8%UK£701.1m
MXCT MaxCyte
7.9x20.5%UK£285.9m
HVO hVIVO
2.2x4.4%UK£149.7m
PPGNZ PolyPeptide Group
3.1x13.2%CHF 921.9m

Price-To-Sales vs Peers: PPGNZ is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does PPGNZ's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies9PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PPGNZ is good value based on its Price-To-Sales Ratio (3.1x) compared to the European Life Sciences industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is PPGNZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PPGNZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.1x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: PPGNZ is expensive based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PPGNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 27.35
CHF 36.25
+32.5%
18.0%CHF 45.20CHF 29.87n/a3
Nov ’25CHF 31.50
CHF 36.25
+15.1%
18.0%CHF 45.20CHF 29.87n/a3
Oct ’25CHF 29.40
CHF 26.85
-8.7%
25.2%CHF 33.63CHF 18.64n/a5
Sep ’25CHF 34.00
CHF 27.79
-18.3%
22.9%CHF 34.16CHF 18.93n/a6
Aug ’25CHF 29.50
CHF 25.84
-12.4%
22.3%CHF 33.51CHF 19.18n/a6
Jul ’25CHF 28.73
CHF 25.84
-10.0%
22.3%CHF 33.51CHF 19.18n/a6
Jun ’25CHF 33.20
CHF 24.50
-26.2%
20.9%CHF 31.04CHF 19.33n/a5
May ’25CHF 30.75
CHF 21.50
-30.1%
21.2%CHF 29.94CHF 16.79n/a5
Apr ’25CHF 30.32
CHF 20.69
-31.8%
14.2%CHF 25.42CHF 16.89n/a5
Mar ’25CHF 15.65
CHF 18.29
+16.9%
18.0%CHF 24.52CHF 15.04n/a5
Feb ’25CHF 14.92
CHF 18.75
+25.7%
18.6%CHF 24.43CHF 14.99n/a4
Jan ’25CHF 17.58
CHF 19.97
+13.6%
13.0%CHF 24.82CHF 17.81n/a5
Dec ’24CHF 18.46
CHF 20.51
+11.1%
11.9%CHF 25.32CHF 18.17n/a6
Nov ’24CHF 16.97
CHF 20.51
+20.9%
11.9%CHF 25.32CHF 18.17CHF 31.506
Oct ’24CHF 16.65
CHF 20.51
+23.2%
11.9%CHF 25.32CHF 18.17CHF 29.406
Sep ’24CHF 24.26
CHF 21.44
-11.6%
10.6%CHF 25.05CHF 18.51CHF 34.006
Aug ’24CHF 20.62
CHF 21.64
+4.9%
15.0%CHF 25.90CHF 16.02CHF 29.505
Jul ’24CHF 18.78
CHF 24.30
+29.4%
12.4%CHF 28.02CHF 20.56CHF 28.736
Jun ’24CHF 24.00
CHF 24.39
+1.6%
12.8%CHF 27.48CHF 20.49CHF 33.205
May ’24CHF 22.56
CHF 25.22
+11.8%
13.4%CHF 28.10CHF 20.95CHF 30.755
Apr ’24CHF 18.52
CHF 25.34
+36.8%
13.7%CHF 28.45CHF 20.99CHF 30.325
Mar ’24CHF 25.14
CHF 28.31
+12.6%
7.9%CHF 32.98CHF 26.04CHF 15.656
Feb ’24CHF 27.44
CHF 39.59
+44.3%
61.1%CHF 93.50CHF 26.39CHF 14.926
Jan ’24CHF 25.46
CHF 39.92
+56.8%
58.9%CHF 91.67CHF 25.87CHF 17.586
Dec ’23CHF 37.20
CHF 44.84
+20.5%
49.5%CHF 91.77CHF 26.71CHF 18.466
Nov ’23CHF 28.96
CHF 46.18
+59.5%
43.2%CHF 91.72CHF 26.70CHF 16.977

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%